Nemera Announces Research Agreement With UFRT for New Nasal Drug Delivery Treatments
Nemera and the Research Center for Respiratory Diseases (CEPR) of Tours University (INSERM U1100) recently announced they have joined forces in a partnership to enhance drug therapeutic effectiveness in the nasal cavity.
The number of applications through the nasal route is expanding. The development of systemic medicinal products through the nasal mucosa is increasing, as well as new treatments directly targeting the central nervous system (nasal administration allows avoiding the blood-brain barrier). The nasal route of administration is easily accessible; it allows a focused efficacy and an outstanding usability, making patients’ lives easier than other types of treatments.
The purpose of this partnership is to develop a new method of nasal administration. This collaboration relies on the expertises of Tours University in respiratory pre-clinical and clinical research, as well and Nemera’s experiences in development of drug delivery devices.
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology & generics industries. Nemera’s services and products cover several key delivery routes: Nasal, buccal, auricular (pumps, valves and actuators for sprays), Inhalation (pMDIs, DPIs), Ophthalmic (multi-dose, preservative-free eyedroppers), Dermal and transdermal (airless & atmospheric dispensers), Parenteral (auto-injectors, pens, safety devices & implanters). Nemera always puts patients first, providing the most comprehensive range of devices in the industry, including off-the-shelf innovative systems, customized design development and customer-owned device manufacturing. For more information, visit www.nemera.net.
The Research Center for Respiratory Diseases (CEPR) is an academic laboratory with a double affiliation: INSERM (UMR 1100) and Université François Rabelais. It develops innovative research for a better understanding of the pathophysiology of respiratory pathologies and improving inhaled therapies. 70 people with multiple skills (immunologists, microbiologists, biochemists, aerosol experts and clinicians) work in the CEPR. The CEPR can develop a continuum of research from the deciphering of the mechanisms of respiratory infection and inflammation up to the development of drug delivery systems to clinical application. For more information, visit www.cepr.inserm.univ-tours.fr/.
Total Page Views: 1159
